Equities
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,715.50
  • Today's Change-19.00 / -1.10%
  • Shares traded4.95m
  • 1 Year change-4.22%
  • Beta0.6081
Data delayed at least 20 minutes, as of Nov 08 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

  • Revenue in JPY (TTM)1.77tn
  • Net income in JPY54.75bn
  • Incorporated1939
  • Employees14.75k
  • Location
    Astellas Pharma Inc2-5-1, Nihombashihon-choCHUO-KU 103-8411JapanJPN
  • Phone+81 332443000
  • Websitehttps://www.astellas.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
4503:TYO since
announced
Transaction
value
Propella Therapeutics IncDeal completed15 Nov 202315 Nov 2023Deal completed-2.28%175.00m
Data delayed at least 20 minutes, as of Nov 08 2024 06:30 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Santen Pharmaceutical Co Ltd302.56bn26.12bn638.31bn3.74k23.892.1214.372.1173.4073.40845.69827.650.72382.583.6880,812,770.006.253.317.774.1057.9259.738.645.211.975.380.163982.218.225.23278.09-3.585.104.88
Rohto Pharmaceutical Co Ltd278.03bn30.33bn798.99bn7.26k25.522.9920.202.87132.56132.561,215.221,129.950.76422.214.3738,300,730.008.428.5411.7011.7957.7658.5911.0210.301.27--0.151319.3913.488.0917.2825.855.2018.61
Ono Pharmaceutical Co Ltd484.30bn95.13bn950.01bn3.85k9.471.148.391.96201.26201.261,026.051,665.850.49872.373.47125,694,000.009.8011.9511.1613.7375.3874.1119.6523.892.80--0.170232.2512.4111.7313.5319.95-6.7912.20
Kyowa Kirin Co Ltd498.98bn83.53bn1.37tn5.97k16.691.6412.732.75156.64156.64936.101,591.790.48781.783.9283,524,780.008.176.289.507.0874.3075.4516.7414.963.06--0.027647.2511.0110.2551.5510.5210.289.86
Eisai Co Ltd753.22bn40.97bn1.51tn11.07k35.411.7518.232.00143.36143.362,634.812,905.110.56730.89333.8968,060,180.003.215.294.327.1679.1276.915.678.681.50--0.178174.13-0.35612.90-23.50-7.72-2.111.30
Shionogi & Co Ltd418.51bn154.57bn1.92tn4.96k11.941.4211.104.59180.74180.74489.151,519.700.2920.91892.9484,393,830.0010.6912.5711.9414.2485.7084.4336.6237.916.48--0.008826.771.973.41-12.403.382.1711.22
Astellas Pharma Inc1.77tn54.75bn3.10tn14.75k56.402.0112.391.7530.4230.42986.34854.610.50601.363.39120,113,500.001.564.592.316.6181.7880.533.097.980.862315.320.377486.615.604.19-82.73-40.179.6213.00
Otsuka Holdings Co Ltd2.27tn151.58bn5.30tn34.39k33.982.0520.142.33279.51279.514,183.344,641.150.6472.404.6865,998,690.004.424.805.595.8871.4268.216.848.361.53--0.117342.1616.149.33-9.188.079.271.92
Takeda Pharmaceutical Co Ltd4.55tn289.99bn6.71tn49.28k23.190.96646.401.48181.90181.902,862.684,365.910.30881.316.2592,248,190.001.971.652.351.9766.0568.056.386.060.77393.080.4219128.425.8715.25-54.561.2829.090.8735
Daiichi Sankyo Co Ltd1.76tn250.40bn9.48tn18.73k37.215.6930.095.39130.86130.86918.60855.860.59131.013.7393,883,960.008.434.9910.516.1476.1169.1014.269.942.24--0.058951.8725.2811.4985.9016.6713.0116.47
Chugai Pharmaceutical Co Ltd1.14tn386.96bn12.16tn7.60k30.796.61--10.64235.14235.14694.161,094.710.58771.223.56150,230,100.0019.9119.2922.9523.9170.4863.5733.8728.394.80--0.0040.14-11.7813.90-13.0828.61-0.894727.23
Data as of Nov 08 2024. Currency figures normalised to Astellas Pharma Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

27.33%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 03 Oct 2024116.85m6.46%
The Vanguard Group, Inc.as of 02 Oct 202464.59m3.57%
BlackRock Fund Advisorsas of 28 Jun 202462.14m3.43%
Nikko Asset Management Co., Ltd.as of 04 Oct 202451.59m2.85%
Daiwa Asset Management Co. Ltd.as of 30 Sep 202450.84m2.81%
BlackRock Japan Co. Ltd.as of 28 Jun 202437.93m2.10%
Wellington Management Co. LLPas of 04 Oct 202432.78m1.81%
Norges Bank Investment Managementas of 30 Jun 202429.68m1.64%
Mitsubishi UFJ Asset Management Co., Ltd.as of 09 Oct 202328.61m1.58%
Geode Capital Management LLCas of 31 Oct 202419.63m1.09%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.